Many patients admitted to psychiatric institutions have a history of risk f
actors for contamination with the hepatitis B and C viruses (HBV and HCV).
Immunization policies for psychiatric institution patients are not widely k
now. A study conducted in a 600-bed psychiatric institution in Paris, Franc
e, to evaluate the proportion of potentially contaminating patients at admi
ssion, as well as immunization use in HBV-negative patients. Serologic mark
ers for the HBV and HCV were looked for prospectively in all patients admit
ted over a two-month period. Immunization use was evaluated in the patients
who had a first serologic test in 1995 or 1996 and follow-up tests until t
he end of 1997. The prospective part of the study demonstrated preadmission
exposure to the HBV in 23.0 +/- 6.0% of patients. This proportion was larg
er in men (26.0%) than in women (14.8%), although the difference was not st
atistically significant (P=0.10). Four patients (2.0%) tested positive for
the HbS Ag. Among the HBV-negative patients, 13.0% received the vaccine; al
l had protective antibody levels. These patients were younger and more like
ly to be first-time admissions (18.4% vs 3.6%, P<0.01). HCV seroprevalence
was 6.0%. Serologic tests for the HBV were requested for 327 patients betwe
en Januar 1995 and december 1996. Among the patients who were seronegative
at admission and received follow-up at the study hospital, only 13.8% were
immunized at this hospital. Of the HCV-positive subjects, 63.3% were also H
BV-positive. None of the HCV-positive HBV-negative subjects received immuni
zation subsequently. Six to eight per cent of patients admitted to the stud
y hospital are potentially contaminating for the I-IBV or HCV The level of
hepatitis B vaccine use is too low, particulary in high-risk patients. Thes
e data indicate a need for policies aimed at effectively preventing HBV and
HCV transmission (information, education, immunization campaigns), both du
ring the psychiatric institution stay and after discharge.